Preston Klassen's Net Worth

$1.64 Million

Estimate Recalculated Apr 24, 2024 05:56PM EST

Who is Preston Klassen?

Preston Klassen has an estimated net worth of $1.64 Million. This is based on reported shares across multiple companies, which include Metacrine, Inc., Orexigen Therapeutics, Inc., ARENA PHARMACEUTICALS INC, Conatus Pharmaceuticals Inc, Regulus Therapeutics Inc., and JATT Acquisition Corp.

SEC CIK

Preston Klassen's CIK is 0001493056

Past Insider Trading and Trends

2011 was Preston Klassen's most active year for acquiring shares with 5 total transactions. Preston Klassen's most active month to acquire stocks was the month of January. 2011 was Preston Klassen's most active year for disposing of shares, totalling 7 transactions. Preston Klassen's most active month to dispose stocks was the month of June. 2019 saw Preston Klassen paying a total of $286,900.00 for 112,900 shares, this is the most they've acquired in one year. In 2019 Preston Klassen cashed out on 46,609 shares for a total of $908,328.24, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Metacrine, Inc. No price found

President & CEO

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-37.83%
-842.21K
$0.47
-$395,839.17
1.38M
Mar 23
Form 4
-41.26%
-380.61K
$0.41
-$157,265.99
541.9K
Jan 26
Form 4
-4.63%
-44.75K
$0.50
-$22,472.08
922.51K
Apr 19
Form 4
+12.11%
104.5K
—
—
967.26K
Apr 14
Form 4
+4,098.95%
842.21K
—
—
862.76K
Feb 27
Form 4
∞
20.55K
$3.64
$74,692.45
20.55K
May 20
Form 4
—
0
—
—
0
Feb 10
Form 3
—
0
—
—
0
No matching records found

Orexigen Therapeutics, Inc. No price found

EVP, Global Development

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+146.00%
6.03K
$2.69
$16,221.30
10.16K
May 30 - Feb 2
Form 4
+225.20%
2.86K
$5.07
$14,506.14
4.13K
May 30 - Feb 3
Form 4
∞
1.27K
$5.34
$6,781.80
1.27K
Nov 29 - Feb 7
Form 4
—
0
$4.41
-$391,759.50
0
Scheduled
Jul 25
Form 4
—
0
$4.43
-$159,598.49
0
Scheduled
May 28
Form 4
—
0
—
—
0
Feb 15
Form 4
—
0
—
—
0
Jan 25
Form 4
—
0
—
—
0
Jul 22 - Jul 25
Form 4
—
0
—
—
0
Jun 10
Form 4
—
0
—
—
0
Mar 2
Form 4
—
0
—
—
0
Jan 18
Form 4
—
0
—
—
0
Sep 20
Form 3
—
0
—
—
0
No matching records found

ARENA PHARMACEUTICALS INC No price found

EVP and CMO

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Mar 1
Form 4
∞
3.99K
$47.32
-$109,261.88
3.99K
Oct 14
Form 4
—
0
$28.58
-$512,166.36
0
Scheduled
Jan 4 - Jan 8
Form 4
—
0
—
—
0
Jan 19
Form 4
—
0
—
—
0
Mar 20
Form 3
—
0
—
—
0
No matching records found

Conatus Pharmaceuticals Inc (HSTO) Snapshot price: $0.34

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 3
—
0
—
—
0
No matching records found

Regulus Therapeutics Inc. (RGLS) Snapshot price: $1.4

President & Head R & D

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Jan 12
Form 4
—
0
—
—
0
Aug 10
Form 4
—
0
—
—
0
Jun 12
Form 3
—
0
—
—
0
No matching records found